Independent review of radiology from a multicentre phase II study evaluating intravenous (IV) topotecan (T) with either cisplatin (C) or etoposide (E) in the first line therapy of extensive disease small cell lung cancer (EDSCLC) by validated response rate (RR)
S. Gwyther, E. Quoix, P. Cardenal, K. Mattson, M. Lymboura, G. RossVolume:
37
Year:
2001
Language:
english
DOI:
10.1016/s0959-8049(01)80707-3
File:
PDF, 178 KB
english, 2001